eCite Digital Repository

Nicotinamide therapy in dialysis patients: A systematic review of randomized controlled trials

Citation

Hussain, S and Singh, A and Alshammari, TM and Habib, A and Hussain, MS and Jha, R and Akhtar, M and Najmi, AK, Nicotinamide therapy in dialysis patients: A systematic review of randomized controlled trials, Saudi Journal of Kidney Diseases and Transplantation, 31, (5) pp. 883-897. ISSN 1319-2442 (2021) [Refereed Article]

Copyright Statement

Copyright 2020 Saudi Center for Organ Transplantation

DOI: doi:10.4103/1319-2442.301195

Abstract

Randomized controlled trials (RCTs) have presented variable findings concerning the reduction of phosphorous level by nicotinamide. This systematic review is aimed to explore the safety and efficacy of nicotinamide in hemodialysis patients and was conducted by adhering to the PRISMA guidelines. Studies for inclusion were identified by running the suitable keywords in PubMed, Embase, and Cochrane Central till June 13, 2018. Cochrane risk of bias tool was used to judge the quality of the included RCTs. The primary outcome was change in serum phosphorus, calcium, and calcium-phosphorus product levels. Change in other biochemical parameters including serum calcium, parathormone, platelets, lipid profile parameters, and the safety profile was considered under secondary outcomes. Review Manager (RevMan v5.3) was used for the risk of bias estimate. A total of 12 articles were qualified for inclusion in this study. All the included RCTs showed a statistically significant reduction in mean serum phosphorous and calcium-phosphorus product levels in the treatment arm as compared to the placebo group. Among several biochemical parameters analyzed, only high-density lipoprotein (HDL) was found to be significantly increased from baseline to the endpoint of the study in the nicotinamide group, while the placebo group showed no significant difference. Flushing and diarrhea, followed by thrombocytopenia, were the most commonly reported adverse events in the treatment group. Nicotinamide was found to be effective in reducing the phosphorous level and calcium-phosphorus product level and increasing the HDL cholesterol level in dialysis patients. The safety profile was found to be satisfactory.

Item Details

Item Type:Refereed Article
Keywords:dialysis
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Intensive care
Objective Division:Health
Objective Group:Clinical health
Objective Field:Efficacy of medications
UTAS Author:Singh, A (Mr Ambrish Singh)
ID Code:144925
Year Published:2021
Web of Science® Times Cited:1
Deposited By:Menzies Institute for Medical Research
Deposited On:2021-06-21
Last Modified:2021-09-14
Downloads:0

Repository Staff Only: item control page